Researchers used evolutionary genetics and CRISPR gene editing tech to develop an innovative treatment for gout. The approach ...

Gene therapies for rare diseases are frequently developed then discarded by drug companies because they can’t afford to ...

Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...

Biomedical engineers at Duke University have successfully conducted experiments to treat damage caused by heart attacks in nonhuman primates using gene therapy for the first time.

The commercial success of existing lipid-lowering medications highlights the enormous market potential for effective ...

Non-exclusive license for Solid Biosciences’ proprietary, next-generation myotropic capsid, AAV-SLB101, to accelerate development of KNA-155 for dysferlinopathySEATTLE--(BUSINESS WIRE)--Kinea Bio Inc.

In a major step toward treating rare neurological diseases, scientists have used gene editing to correct mutations inside the ...

Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s ...